首页 > 市场调查报告书 > 製药

药物开发临床实验开发业务受託机关

市场调查报告书

商品编码

1968009

全球临床前CRO市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Preclinical CRO Market Size, Share, Trends & Growth Analysis Report 2026-2034

出版日期: 2026年02月05日 | 出版商:

Value Market Research | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

预计临床前 CRO 市场将从 2025 年的 68.3 亿美元成长到 2034 年的 140.2 亿美元，2026 年至 2034 年的复合年增长率为 8.31%。

受製药和生物技术领域研发活动日益活跃的推动，全球临床前CRO市场正迅速扩张。企业将临床前试验外包，以降低营运成本并缩短药物研发週期。对包括生物製药和基因疗法在内的新型治疗方法的投资不断增加，也推动了对专业研究服务的需求。随着药物研发管线日趋复杂，对专业合约研究组织（CRO）的需求进一步成长。

试管内测试、动物模型和数据分析方面的技术进步正在提高研究效率。随着安全性和有效性测试的监管要求日益严格，对经验丰富的合约研究组织（CRO）合作伙伴的依赖也越来越强。新兴生物技术Start-Ups倾向于外包，以便专注于其核心业务。此外，学术机构与CRO之间合作的加强也促进了创新和研究能力的提升。

展望未来，全球研发投入的成长可望推动市场发展。人工智慧药物发现和预测毒理学等先进技术的引入预计将拓展服务范围。亚太地区可望凭藉成本优势和不断完善的研发基础设施，成为关键成长区域。持续创新和策略伙伴关係有望支撑市场的长期扩张。

区域分析
北美市场分析、洞察与预测
- 我们
- 加拿大
- 墨西哥
欧洲市场分析、洞察与预测
- 英国
- 法国
- 德国
- 义大利
- 俄罗斯
- 其他欧洲国家
亚太市场分析、洞察与预测
- 印度
- 日本
- 韩国
- 澳洲
- 东南亚
- 其他亚太国家
拉丁美洲市场分析、洞察与预测
- 巴西
- 阿根廷
- 秘鲁
- 智利
- 其他拉丁美洲国家
中东和非洲市场分析、洞察与预测
- 沙乌地阿拉伯
- UAE
- 以色列
- 南非
- 其他中东和非洲国家

第八章竞争情势

最新趋势
公司分类
供应链和销售管道合作伙伴（根据现有资讯）
市场占有率和市场定位分析（基于现有资讯）
供应商情况（基于现有资讯）
策略规划

第九章：公司简介

主要公司的市占率分析
公司简介
- WuXi AppTec Inc
- Labcorp（Laboratory Corporation Of America Holdings）
- Eurofins Scientific SE
- Medpace Holdings Inc
- Charles River Laboratories International Inc
- Intertek Group Plc
- PPD（Thermo Fisher Scientific Inc.）
- ICON Plc（Formerly Including PRA Health Sciences）
- Covance（LabCorp）
- Crown Bioscience

简介目录

Product Code: VMR112110008

The Preclinical CRO Market size is expected to reach USD 14.02 Billion in 2034 from USD 6.83 Billion (2025) growing at a CAGR of 8.31% during 2026-2034.

The Global Preclinical CRO Market is expanding rapidly due to increasing pharmaceutical and biotechnology research activities. Companies are outsourcing preclinical studies to reduce operational costs and accelerate drug development timelines. Rising investments in novel therapeutics, including biologics and gene therapies, are fueling demand for specialized research services. Growing complexity of drug pipelines is further strengthening the need for expert contract research organizations.

Technological advancements in in vitro testing, animal models, and data analytics are enhancing research efficiency. Regulatory requirements for safety and efficacy testing are becoming more stringent, driving reliance on experienced CRO partners. Emerging biotech startups prefer outsourcing to focus on core competencies. Additionally, increased collaboration between academic institutions and CROs is boosting innovation and research capabilities.

Looking ahead, the market is expected to benefit from rising R&D expenditure globally. Adoption of advanced technologies such as AI-driven drug discovery and predictive toxicology will likely expand service offerings. Asia-Pacific is anticipated to emerge as a significant growth region due to cost advantages and expanding research infrastructure. Continuous innovation and strategic partnerships are expected to sustain long-term market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Service

Bioanalysis and DMPK studies
Toxicology Testing
Compound Management
Process R&D
Chemistry
Safety Pharmacology
Others

By Model Type

Patient Derived Organoid (PDO) Model
Patient Derived Xenograft Model

By End-use

Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

COMPANIES PROFILED

WuXi AppTec Inc, Labcorp Laboratory Corporation of America Holdings, Eurofins Scientific SE, Medpace Holdings Inc, Charles River Laboratories International Inc, Intertek Group plc, PPD Thermo Fisher Scientific Inc, ICON plc formerly including PRA Health Sciences, Covance LabCorp, Crown Bioscience
We can customise the report as per your requirements.

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL PRECLINICAL CRO MARKET: BY SERVICE 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Service
4.2. Bioanalysis and DMPK studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Toxicology Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Compound Management Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Process R&D Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Chemistry Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.7. Safety Pharmacology Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PRECLINICAL CRO MARKET: BY MODEL TYPE 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Model Type
5.2. Patient Derived Organoid (PDO) Model Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Patient Derived Xenograft Model Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PRECLINICAL CRO MARKET: BY END-USE 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast End-use
6.2. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Government and Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Medical Device Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PRECLINICAL CRO MARKET: BY REGION 2022-2034(USD MN)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Service
- 7.2.2 By Model Type
- 7.2.3 By End-use
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Service
- 7.3.2 By Model Type
- 7.3.3 By End-use
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Service
- 7.4.2 By Model Type
- 7.4.3 By End-use
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Service
- 7.5.2 By Model Type
- 7.5.3 By End-use
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Service
- 7.6.2 By Model Type
- 7.6.3 By End-use
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PRECLINICAL CRO INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 WuXi AppTec Inc
- 9.2.2 Labcorp (Laboratory Corporation Of America Holdings)
- 9.2.3 Eurofins Scientific SE
- 9.2.4 Medpace Holdings Inc
- 9.2.5 Charles River Laboratories International Inc
- 9.2.6 Intertek Group Plc
- 9.2.7 PPD (Thermo Fisher Scientific Inc.)
- 9.2.8 ICON Plc (Formerly Including PRA Health Sciences)
- 9.2.9 Covance (LabCorp)
- 9.2.10 Crown Bioscience

02-2729-4219

+886-2-2729-4219

License/价格

全球临床前CRO市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Preclinical CRO Market Size, Share, Trends & Growth Analysis Report 2026-2034